News | May 29, 2024
Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Subscribe To Our Newsletter & Stay Updated
